Full Text View
Tabular View
No Study Results Posted
Related Studies
Pancreatic Islet Mass in Pregnancy
This study is currently recruiting participants.
Verified by University of Alberta, January 2009
First Received: October 23, 2007   Last Updated: January 6, 2009   History of Changes
Sponsored by: University of Alberta
Information provided by: University of Alberta
ClinicalTrials.gov Identifier: NCT00548522
  Purpose

Type 1 diabetic women have a decrease in insulin requirements during early pregnancy. Preliminary evidence suggests this decrease may be secondary to the regeneration of pancreatic B-cells during pregnancy During the second and third trimesters, insulin requirements in Type 1 diabetic women progressively increase until approximately 36 weeks gestation at which time there is a plateau, and frequently, a drop in insulin requirements. We hypothesize that there is regeneration of pancreatic islet cell mass in Type 1 diabetic women during pregnancy. In a cross-sectional study, we will use the acute insulin c-peptide response to arginine to determine if pancreatic islet mass increases at 12 and 36 weeks gestation. Type 1 diabetic women who are not pregnant, who are at 12 and 36 weeks gestation, and who are 6 weeks post-partum will undergo an intravenous arginine tolerance test following an overnight fast. If we find that there is regeneration of beta cells it opens the possibility that therapy may be directed to the same end for people with Type 1 diabetes.


Condition
Type 1 Diabetes
Pregnancy

MedlinePlus related topics: Diabetes Diabetes Type 1
U.S. FDA Resources
Study Type: Observational
Study Design: Case-Only, Cross-Sectional
Official Title: Pancreatic Islet Mass in Pregnancy - Pilot Study

Further study details as provided by University of Alberta:

Primary Outcome Measures:
  • The documentation of Cpeptide in women with type 1 diabetes who are pregnant [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Biospecimen Description:

Plasma Samples kept for batching of antibody assays


Estimated Enrollment: 30
Study Start Date: August 2007
Estimated Study Completion Date: November 2009
Groups/Cohorts
1
Pregnant (12 - 16 wks) women with Type 1 diabetes
2
Pregnant women (34-38 wks) with Type 1 diabetes
3
Post partum women with Type 1 diabetes
4
Non pregnant women with Type 1 diabetes

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Pregnant women with Type 1 diabetes

Criteria

Inclusion Criteria:

  • Signed informed consent
  • Females with Type 1 diabetes for at least 5 years
  • Diabetes onset < 21 years
  • Lean at diabetes onset
  • Insulin required from diagnosis
  • Willing to undergo intravenous arginine tolerance tests

Exclusion Criteria:

  • Inability to provide informed consent
  • Any medical condition that would preclude safe conduct of the intravenous arginine
  • A family history which includes three generations of family members with the diagnosis of diabetes mellitus
  • Women with elevated serum creatinine as arginine is excreted by the kidneys.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00548522

Contacts
Contact: Edmond A Ryan, MD 780 407 3636 edmond.ryan@ualberta.ca
Contact: Judy Germsheid, RN 780 407 8630 judyg@ualberta.ca

Locations
Canada, Alberta
University of Alberta Recruiting
Edmonton, Alberta, Canada, T6G 2S2
Contact: Edmond A Ryan, MD     780 407 3636     edmond.ryan@ualberta.ca    
Contact: Judy Germsheid, RN     780 407 8630     judyg@ualberta.ca    
Principal Investigator: Edmond A Ryan, MD            
Sub-Investigator: Carmen Young, MD            
University of Alberta Hospital Recruiting
Edmonton, Alberta, Canada, T6G 2B7
Contact: Edmond A Ryan, MD     780 407 3636     Edmond.Ryan@Ualberta.ca    
Contact: Judy Germsheid, RN     780 407 8630     judyg@Ualberta.ca    
Principal Investigator: Edmond A Ryan, MD            
Sponsors and Collaborators
University of Alberta
Investigators
Principal Investigator: Edmond A Ryan, MD University of Alberta
  More Information

No publications provided

Responsible Party: University of Alberta ( Edmond A Ryan )
Study ID Numbers: UAHREB4503
Study First Received: October 23, 2007
Last Updated: January 6, 2009
ClinicalTrials.gov Identifier: NCT00548522     History of Changes
Health Authority: Canada: Health Canada

Keywords provided by University of Alberta:
Type 1 Diabetes
Pregnancy
Islet Mass
C-peptide

Study placed in the following topic categories:
Autoimmune Diseases
Metabolic Diseases
Diabetes Mellitus, Type 1
Diabetes Mellitus
Endocrine System Diseases
Diabetes Mellitus Type 1
Endocrinopathy
Glucose Metabolism Disorders
Metabolic Disorder

Additional relevant MeSH terms:
Autoimmune Diseases
Metabolic Diseases
Immune System Diseases
Diabetes Mellitus, Type 1
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on May 07, 2009